Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMeridian Health Plan MI step therapy Coverage | Op…
    Ask Trek AI about this page
    CurrentMeridian Health Plan of MichiganPolicy N/A

    2026 Step Therapy Criteria — Pharmacy step edits for behavioral health drugs

    Customize your policy alerts

    Sign up for all meridian_health_plan_of_michigan policy alerts

    Know when meridian_health_plan_of_michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Meridian Health Plan of Michigan step therapy requirements for select antidepressants, antipsychotics (oral), dextromethorphan/bupropion products, and trazodone; applies to medication coverage and prior authorization decisions for members of the plan.

    Policy Summary
    PayerMeridian Health Plan of Michigan
    Policy2026 Step Therapy Criteria — Pharmacy step edits for behavioral health drugs
    Policy CodePolicy N/A
    Change TypeAdministrative review — no material clinical changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trials of required Step 1 agents (at least a 1‑day supply within the prior 180 days) or provide allowable exception evidence when requesting Step 2 products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4major drug groups
    Step 1/Step 2step structure
    180 dayslookback window
    Exxua/Auvelity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    exceptions noted
    2therapy steps

    Step Therapy Coverage Criteria

    Antidepressants — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Antidepressant step requirement: Coverage for Step 2 antidepressant products is provided if ONE Step 1 drug has been tried (at least a 1-day supply in the prior 180 days).1 drug trial in 180 days

    Step 1 list: Bupropion SR/XL, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Venlafaxine IR/ER.

    Exceptions: Approve Exxua (step 2) without prerequisite trial if patient has suicidal ideation or if currently taking or previously took Exxua.

    Oral Antipsychotics — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Antipsychotic step requirement: Coverage for Fanapt (Step 2) is provided if TWO Step 1 oral antipsychotics have been tried (each at least a 1-day supply in the prior 180 days).2 drug trials in 180 days

    Step 1 list includes oral formulations of Aripiprazole, Asenapine Maleate, Brexpiprazole, Cariprazine HCl, Lumateperone Tosylate, Lurasidone HCl, Olanzapine, Paliperidone, Quetiapine Fumarate, Risperidone, Xanomeline/Trospium Chloride, or Ziprasidone HCl.

    Current/prior use: Approve Fanapt if the patient is currently taking Fanapt or has taken Fanapt in the past.

    Auvelity (Dextromethorphan/Bupropion) — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Auvelity step requirement: Coverage for Auvelity is approved if the patient has tried a generic SSRI or SNRI AND bupropion for any trial duration within the previous 180 days.SSRI/SNRI + bupropion within 180 days

    Specific Step 1 lists include multiple SSRI/SNRI and bupropion formulations.

    Exceptions: Approve Auvelity without prerequisite trials for patients with current suicidal ideation, for agitation associated with dementia due to Alzheimer's disease, or if patient is currently taking or has previously taken Auvelity.

    Trazodone — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Trazodone step structure: Trazodone has Step 1 (generic trazodone tablet formulations) and Step 2 (brand Raldesy oral solution); coverage of Step 2 requires prior Step 1 trial unless an exception applies.

    Step 1 includes trazodone 100 mg and 150 mg tablets; Step 2 is Raldesy 10 mg/mL oral solution. Patient must have tried a tablet dosage form of generic trazodone (>=1-day supply in prior 180 days) before Raldesy coverage unless exception applies.

    Coverage criteria for Raldesy

    Coverage for Raldesy (trazodone oral solution) is provided when ANY of the following conditions are met:

    Step therapy allowance and exceptions: Approve Raldesy if the patient has tried a tablet dosage form of generic trazodone (at least a 1-day supply in the prior 180 days).at least 1-day supply in prior 180 days

    Step 1 tablet options listed: trazodone 50 mg, 100 mg, 150 mg; Step 2 option: Raldesy 10 mg/mL oral solution

    Swallowing impairment: Approve Raldesy if the patient has difficulty swallowing tablets or cannot swallow tablets.

    Document swallowing difficulty as part of prior authorization.

    Current or prior Raldesy use: Approve Raldesy if the patient is currently taking Raldesy or has taken Raldesy at any time in the past.

    Document current or prior use of Raldesy to support approval.

    Step 1 — Initial Therapy

    Step 1 — Initial therapy lists of preferred agents

    Step 1 lists (initial preferred agents)

    Antidepressant Step 1 list: Lists of numerous generic antidepressant formulations considered Step 1 (see policy Step 1 lists) including multiple bupropion, citalopram, duloxetine, escitalopram, fluoxetine, and venlafaxine formulations.

    Specific products enumerated in the Step 1 lists (chunks 4 and 13).

    Trazodone Step 1: Trazodone 100 mg and 150 mg tablets listed as Step 1 initial agents.

    Step 1 — tablet trial (preferred initial agents — tablet dosage forms)

    Step 1 — preferred initial agents (tablet dosage forms):

    Step 1 agents: trazodone 100 mg tablet; trazodone 150 mg tablet; trazodone 50 mg tablet

    Step Therapy Rules and Tables

    RuleRequirement / Notes
    Step therapy requirement
    Members must trial the listed Step 1 agents before coverage of Step 2 products; a Step 1 trial is defined as at least a 1-day supply within the prior 180 days. Exceptions include documented current use or prior use of the Step 2 product and specified clinical exceptions (e.g., suicidal ideation for select products).
    StepRequired trial / Allowed options
    Step 1 (tablet trial)
    Trial of a tablet dosage form of generic trazodone — listed tablet strengths: 50 mg, 100 mg, or 150 mg. Trial must be at least a 1-day supply within the prior 180 days to satisfy Step 1 requirement for Step 2 consideration.
    Step 2 (Raldesy)
    Raldesy (trazodone 10 mg/mL oral solution) may be approved if Step 1 trial criteria are met, or if the patient cannot swallow tablets, or if the patient is currently taking or has previously taken Raldesy.

    Prior Authorization & Documentation Requirements

    Prior Authorization

    PA requires documented Step 1 trial or allowed exception

    Prior authorization requires evidence that the member has met the Step 1 trial requirement within the prior 180 days (at least a 1-day supply of a listed Step 1 agent), or documentation of an allowable exception such as current use, prior use of the Step 2 product, or documented suicidal ideation where specified.

    • Step 1 trial = at least a 1-day supply in the prior 180 days.
    • Exceptions include current or prior use of the Step 2 product and suicidal ideation for specified products.
    Prior Authorization

    Raldesy prior auth requires tablet trial or exception

    Prior authorization for Raldesy is contingent on meeting the trazodone step therapy criteria: a documented trial of a generic trazodone tablet (≥1-day supply within the prior 180 days) or documentation of an allowed exception (difficulty swallowing tablets, or current/prior use of Raldesy).

    • Step 1 tablet options: trazodone 50 mg, 100 mg, or 150 mg.

    Lookback Window, Definitions, and Exceptions

    Prior trial lookback window
    Lookback windowPrior trial defined as at least a 1-day supply within the prior 180 days
    Applies toAntidepressant and other class Step 1 trials required for Step 2 approvals as specified in policy
    Documentation requiredPrescription record or medication history showing ≥1-day supply during the 180-day lookback
    Effect of missing trialLack of documented trial in the 180-day window may result in coverage denial for Step 2 products (unless an exception applies)
    Step 1 / Step 2 trial definition and requirements
    Definition of a trialA trial is met by documentation of at least a 1-day supply of a listed Step 1 drug within the prior 180 days

    Continuation and Renewal Considerations

    Continuation / Current or prior use exceptions — criteria for continuation or renewal when prior use documented

    Continuation/renewal exceptions — approve when ANY of the following are met:

    Prior/current use allows approval: Approve the Step 2 product if the patient is currently taking the Step 2 product or has taken it in the past (documented).

    Stated for Exxua, Fanapt, and Auvelity in policy details.

    Policy Background

    This policy organizes selected behavioral‑health medications into a two‑tier Step 1 / Step 2 structure within each drug class. For each class (antidepressants, oral antipsychotics, dextromethorphan/bupropion products, and trazodone), Step 1 lists lower‑step, generally generic agents that must be tried before coverage of higher‑step products is considered; Step 2 lists the higher‑step or brand products subject to prior authorization.

    Prior trials of Step 1 agents are assessed using a lookback window of 180 days. A qualifying Step 1 trial is documented by evidence of at least a 1‑day supply of a listed Step 1 agent within that 180‑day period. Where specified in the class criteria, one Step 1 trial (antidepressants) or two Step 1 trials (oral antipsychotics) are required before Step 2 coverage will be provided.

    The policy also specifies clinically‑based exceptions that permit approval of certain Step 2 agents without prerequisite Step 1 trials. Examples include approval of Exxua or Auvelity when current suicidal ideation is documented, and allowance for Step 2 approval when the member is currently taking or has previously taken the Step 2 product.

    For trazodone specifically, the policy requires a tablet dosage trial of generic trazodone (Step 1) before approving the Step 2 product Raldesy, but allows Raldesy to be approved if the patient has difficulty swallowing tablets or is currently/formerly taking Raldesy.

    Policy Revision History

    2026-08-01policy_updateLatest

    Policy updated and published with effective date 2026-08-01 reflecting step therapy criteria for antidepressants, oral antipsychotics, dextromethorphan/bupropion (Auvelity), and trazodone (including Raldesy).

    2026-08-01reviewLatest

    Last policy review completed (document updated 08/01/2026).

    Policy Summary
    PayerMeridian Health Plan of Michigan
    Policy2026 Step Therapy Criteria — Pharmacy step edits for behavioral health drugs
    Policy CodePolicy N/A
    Change TypeAdministrative review — no material clinical changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trials of required Step 1 agents (at least a 1‑day supply within the prior 180 days) or provide allowable exception evidence when requesting Step 2 products.
    SourceLink
    On This Page
    Step Therapy Coverage CriteriaStep 1 — Initial TherapyStep Therapy Rules and TablesPrior Authorization & Documentation RequirementsLookback Window, Definitions, and ExceptionsContinuation and Renewal ConsiderationsPolicy BackgroundPolicy Revision History
    N/A

    Patient must have tried a tablet dosage form of generic trazodone (>=1-day supply in prior 180 days) before Raldesy coverage will be provided unless exception applies.

  1. Step 2 option: Raldesy 10 mg/mL oral solution.
  2. Note

    General step therapy: require Step 1 before Step 2 unless exception

    Members must trial the listed Step 1 agents for the applicable drug class before Step 2 products will be approved, unless a stated exception applies (e.g., current/prior use of the Step 2 product or documented suicidal ideation for specific products).

    • Step 1 trial is defined as at least a 1-day supply within the prior 180 days.
    • Exceptions are explicitly stated per product (for example, Exxua and Auvelity).
    Step Therapy

    Two-step sequence for trazodone → Raldesy

    Trazodone step therapy follows a two-step sequence: Step 1 requires a trial of generic trazodone tablets (listed strengths); Step 2 is Raldesy oral solution, which may be approved only if Step 1 criteria are met or a specified exception is documented.

    • Step 1: trazodone 50 mg, 100 mg, or 150 mg tablet trial.
    • Step 2: Raldesy 10 mg/mL oral solution; approval allowed for inability to swallow tablets or current/prior Raldesy use.
    Documentation Required

    Document prior Step 1 trials or qualifying exception

    Document prior trials of required Step 1 agents by showing at least a 1-day supply within the prior 180 days, or provide documentation of current/prior use of the requested Step 2 product or a qualifying clinical exception.

    • Acceptable evidence: prescription records showing ≥1-day supply in the prior 180 days or clinical notes documenting current/prior use.
    • Exceptions (e.g., suicidal ideation, swallowing difficulty) must be documented in the record.
    Documentation Required

    Documentation for tablet trial or swallowing difficulty (Raldesy)

    When requesting Raldesy, document prior use of a tablet dosage form of generic trazodone (at least a 1-day supply in the prior 180 days) or document documented swallowing difficulty or current/past use of Raldesy to support approval.

    • Required tablet trial evidence: at least a 1-day supply of trazodone tablet in prior 180 days.
    • If patient cannot swallow tablets, document swallowing difficulty in the clinical record.
    Denial Risk

    Denial risk if Step 1 antidepressant trial not documented

    Coverage will be denied for Step 2 antidepressant requests if the prerequisite Step 1 drug trial (at least a 1-day supply within the prior 180 days) is not documented and no exception applies.

    • Ensure the record shows the required Step 1 agent trial or an applicable exception before submitting prior authorization.
    Denial Risk

    Denial risk if two Step 1 oral antipsychotic trials not documented

    Coverage will be denied for Step 2 oral antipsychotic (Fanapt) requests unless the patient has tried two Step 1 oral antipsychotics (each at least a 1-day supply within the prior 180 days) or an allowed exception is documented.

    • Trials of two distinct Step 1 oral antipsychotics must be documented in the prior 180 days.
    • A trial of the brand-name equivalent of a generic Step 1 product counts toward the requirement.
    Step Therapy

    Auvelity requires SSRI/SNRI plus bupropion trial or exception

    Coverage for Auvelity will be denied unless the patient has trialed a generic SSRI or SNRI AND bupropion within the prior 180 days, unless an exception (current suicidal ideation, agitation with Alzheimer's disease, or current/prior Auvelity use) is documented.

    • Required: SSRI or SNRI plus bupropion trial within previous 180 days (any duration).
    • Document any applicable exception in the clinical record to avoid denial.
    Denial Risk

    Raldesy prior tablet trial required (or documented exception)

    For Raldesy, coverage requires a prior trial of a tablet dosage form of generic trazodone (at least a 1-day supply in the prior 180 days); approval may alternatively be supported by documented inability to swallow tablets or current/prior use of Raldesy.

    • Prior tablet trial: at least a 1-day supply of trazodone tablet within prior 180 days.
    • Allowed exceptions: documented swallowing difficulty or current/past Raldesy use.
    Step 1 to Step 2 requirementStep 2 products require documented prior trials of the specified Step 1 agents per drug class (one Step 1 trial for antidepressants; two Step 1 oral antipsychotics for Fanapt; SSRI/SNRI plus bupropion for Auvelity)
    Acceptable evidenceCurrent use, prior use, or prescription fill records demonstrating the 1-day supply within 180 days satisfy the trial requirement
    Exceptions notedExceptions (e.g., continuation/current or prior use of the Step 2 product) are addressed separately in the policy
    Exception for suicidal ideation
    Suicidal ideation exceptionCertain Step 2 products (example: Auvelity; Exxua noted elsewhere) may be approved without prerequisite Step 1 trials if the patient has current suicidal ideation
    Other qualifying exceptionsAuvelity may also be approved without prerequisite trials for agitation associated with dementia due to Alzheimer's disease, or if the patient is currently or previously taking Auvelity
    Documentation neededProvider must document the presence of current suicidal ideation (or other qualifying condition) to support approval without prior Step 1 trials